Overview

Cell therapy, utilizing autologous (patient-derived) or allogeneic (donor-derived) cells, is transforming the fields of immunotherapy, cancer treatment, and regenerative medicine.

GenScript enhances the production of both gene-modified and non-gene-modified cell therapies by delivering a comprehensive array of top-tier reagents, advanced automation tools, CRISPR, mRNA, gene synthesis, plasmid and viral vector production, along with expert regulatory support. From research use (RUO) to GMP-grade materials, we ensure a reliable supply chain and timely delivery to meet your development needs.

Partner with GenScript for end-to-end solutions that accelerate your therapy’s journey from discovery to clinical success.

Cell Therapy Development Process

The development of cell therapies is a systematic process encompassing four critical stages:

1.Target Discovery and Validation: Identifying viable therapeutic targets and confirming their potential for clinical application.

2.CAR/TCR Design and Optimization:Engineering and refining Chimeric Antigen Receptors (CAR) or T-Cell Receptors (TCR) for precision targeting and enhanced functionality.

3.Preclinical Development: Performing rigorous in vitro and in vivo evaluations to ensure safety, efficacy, and scalability.

4.Clinical Development:Transitioning to human trials, optimizing protocols, and preparing for regulatory approval.

Target Discovery and
Validation
1
CAR/TCR Design
and Optimization
2
Preclinical
Development
3
Clinical
Development
4

CAR/TCR Design and Optimization

Preclinical Development

Solutions Advantage

Support teams icon

Experienced service and Support teams

GMP facilities icon

GMP facilities and Manufacturing excellence

Quality and Regulatory Compliance icon

Quality and Regulatory Compliance

Flexibility icon

Flexibility – End-to-End CRO and CDMO Service

Industry Insights

Cell Therapy Resources

Explore our technologies and learn more about Cell Therapy Solution. Find the information and resources you need by browsing through our educational material.

Explore our technologies and learn more about Cell Therapy . Find the information and resources you need by browsing through our educational webinar.

Alexander Marson, MD, PhD
Reprogramming Human T Cells with CRISPR

Alexander Marson, MD, PhD
Director, Gladstone-UCSF Institute of Genomic Immunology

Learn More
Anna Pasetto, PhD, Assistant Professor
TCR targets validation through T cell activation

Anna Pasetto, PhD, Assistant Professor
Managing director of pre-GMP facility
Department of Laboratory Medicine, Karolinska Institutet

Learn More
Joshua Burgess, PhD
Identification and Characterization of a Novel Biomarker for Cancer Therapy

Joshua Burgess, PhD
Advance Queensland Early Career Research Fellow of Translational Research Institute, Queensland University of Technology

Learn More
JJ Joseph Melenhorst, PhD
Response to Second Generation CAR T Cell Therapy: It takes (at least) Two to Tango

J Joseph Melenhorst, PhD
Professor, Pathology and Laboratory Medicine, University of Pennsylvania and Director, Biomarker Program, Parker Institute for Cancer Immunotherapy, UPenn

Learn More
Ramarao Vepachedu, PhD
CRISPR/Cas9-based genome editing for autologous CAR-T cell production

Ramarao Vepachedu, PhD
Development Scientist IV, Leidos Biomedical Research, Inc

Learn More
Matthew Porteus, MD, PhD
Targeted Integration in Stem Cells

Matthew Porteus, MD, PhD
Professor, Stanford University, School of Medicine

Learn More
Shondra M. Pruett-Miller, PhD
Operationalizing Genome Editing Across a Broad Range of Genomic and Cellular Targets

Shondra M. Pruett-Miller, PhD
Director, St. Jude Children's Research Hospital Comprehensive Cancer Center

Learn More
img bg

Reproducible and reliable research starts with high quality materials Interested in accelerating your research with us?

Speak To A Specialist